Epilogue: New Drugs for Neglected Diseases
In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion (year 2000 U.S. dollars) per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real (inflation-adjusted) rate o...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Cambridge Univ. Press
2011
|
| In: |
Cambridge quarterly of healthcare ethics
Year: 2011, Volume: 20, Issue: 2, Pages: 329-334 |
| Online Access: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1827985097 | ||
| 003 | DE-627 | ||
| 005 | 20230426094854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221220s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/S0963180110000988 |2 doi | |
| 035 | |a (DE-627)1827985097 | ||
| 035 | |a (DE-599)KXP1827985097 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Pogge, Thomas |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Epilogue: New Drugs for Neglected Diseases |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion (year 2000 U.S. dollars) per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real (inflation-adjusted) rate of 7.4% annually. According to these estimates, the innovation cost per new medicine today is about $2.1 billion (year 2000 U.S. dollars) or $2.65 billion (year 2010 U.S. dollars). | ||
| 700 | 1 | |a Hollis, Aidan |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cambridge quarterly of healthcare ethics |d Cambridge : Cambridge Univ. Press, 1992 |g 20(2011), 2, Seite 329-334 |h Online-Ressource |w (DE-627)306655039 |w (DE-600)1499985-7 |w (DE-576)081985010 |x 1469-2147 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2011 |g number:2 |g pages:329-334 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/S0963180110000988 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/article/epilogue-new-drugs-for-neglected-diseases/19504A82A0B95C7F822D212384B43464 |x Verlag |z lizenzpflichtig |3 Volltext |
| 935 | |a mteo | ||
| 936 | u | w | |d 20 |j 2011 |e 2 |h 329-334 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4235390007 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1827985097 | ||
| LOK | |0 005 20221220052659 | ||
| LOK | |0 008 221220||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-12-06#BACF3C4F0F50622F6B6623730244B4FCFD90B5FB | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||